{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-043761","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2024-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.342401+00:00","generated_at":"2026-05-30T10:00:08.100994+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aquestive presents Anaphylm data showing consistent PK/PD regardless of film movement","bullets":["87.5% of subjects had no film movement; 12.5% showed movement with no significant PK/PD impact.","Geometric mean Cmax: 351.14 pg/mL (movement) vs 490.27 pg/mL (no movement); p=0.49.","Median Tmax was 12 minutes for both groups; comparable to epinephrine injection.","Data supports Anaphylm as a potential needle-free epinephrine option for anaphylaxis if FDA-approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-043761","json":"https://secwatch.observer/filing/0001628280-24-043761.json","markdown":"https://secwatch.observer/filing/0001628280-24-043761.md","text":"https://secwatch.observer/filing/0001628280-24-043761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024043761/0001628280-24-043761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828024043761/aqst-20241025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T10:00:08.100994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}